{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:41:24Z","timestamp":1792680084553,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["fertstertreports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["F&S Reports"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.xfre.2025.09.005","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T02:39:44Z","timestamp":1758076784000},"page":"420-427","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Reproductive impact of immune checkpoint inhibitor therapy in women with melanoma"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2566-6215","authenticated-orcid":false,"given":"Quinn","family":"Rhodes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terri L.","family":"Woodard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Detti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Shott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"McQuade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie J.","family":"McKenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xfre.2025.09.005_bib1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/clinpract13010003","article-title":"The role of immune checkpoint inhibitors in cancer therapy","volume":"13","author":"Basudan","year":"2022","journal-title":"Clin Pract"},{"key":"10.1016\/j.xfre.2025.09.005_bib2","article-title":"Patterns in cancer incidence among people younger than 50 years in the US, 2010 to 2019","volume":"6","author":"Koh","year":"2023","journal-title":"J Am Med Assoc Netw Open"},{"key":"10.1016\/j.xfre.2025.09.005_bib3","doi-asserted-by":"crossref","DOI":"10.1177\/20503121211034366","article-title":"New approaches and procedures for cancer treatment: current perspectives","volume":"9","author":"Debela","year":"2021","journal-title":"SAGE Open Med"},{"key":"10.1016\/j.xfre.2025.09.005_bib4","doi-asserted-by":"crossref","DOI":"10.1177\/2042018819896182","article-title":"Immunotherapy-induced endocrinopathies: assessment, management and monitoring","volume":"10","author":"Nogueira","year":"2019","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.xfre.2025.09.005_bib5","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/eji.201948382","article-title":"Immune checkpoint molecules in pregnancy: focus on regulatory T cells","volume":"50","author":"Zhang","year":"2020","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.xfre.2025.09.005_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4137\/CMED.S22469","article-title":"Immune checkpoint inhibitor therapy associated hypophysitis","volume":"8","author":"Mahzari","year":"2015","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"10.1016\/j.xfre.2025.09.005_bib7","doi-asserted-by":"crossref","first-page":"312","DOI":"10.4103\/tcmj.tcmj_255_19","article-title":"Role of hypothyroidism and associated pathways in pregnancy and infertility: clinical insights","volume":"32","author":"Koyyada","year":"2020","journal-title":"Tzu Chi Med J"},{"key":"10.1016\/j.xfre.2025.09.005_bib8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","article-title":"A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","author":"de Filette","year":"2019","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.xfre.2025.09.005_bib9","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz112","article-title":"Fertility and pregnancy in women with hypopituitarism: a systematic literature review","volume":"105","author":"Vila","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.xfre.2025.09.005_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s43018-022-00413-x","article-title":"Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice","volume":"3","author":"Winship","year":"2022","journal-title":"Nat Cancer"},{"key":"10.1016\/j.xfre.2025.09.005_bib11","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/CJI.0000000000000418","article-title":"Immune checkpoint inhibitor exposure in pregnancy: a scoping review","volume":"45","author":"Salehi","year":"2022","journal-title":"J Immunother"},{"key":"10.1016\/j.xfre.2025.09.005_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100262","article-title":"Immune checkpoint inhibitor administration during pregnancy: a case series","volume":"6","author":"Andrikopoulou","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.xfre.2025.09.005_bib13","article-title":"Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review","volume":"6","author":"Garutti","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.xfre.2025.09.005_bib14","article-title":"Immune checkpoint inhibitor use during pregnancy and outcomes in pregnant individuals and newborns","volume":"7","author":"Gougis","year":"2024","journal-title":"J Am Med Assoc Netw Open"},{"key":"10.1016\/j.xfre.2025.09.005_bib15","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1200\/JCO.2018.78.1914","article-title":"Fertility preservation in patients with cancer: ASCO clinical practice guideline update","volume":"36","author":"Oktay","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.xfre.2025.09.005_bib16","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.fertnstert.2005.03.013","article-title":"Fertility preservation and reproduction in cancer patients","volume":"83","year":"2005","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfre.2025.09.005_bib17","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/14737140.2017.1335199","article-title":"Anticancer treatments and female fertility: clinical concerns and role of oncologists in oncofertility practice","volume":"17","author":"Salama","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.xfre.2025.09.005_bib18","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1158\/1078-0432.CCR-16-0712","article-title":"U.S. FDA approval summary: nivolumab for treatment of unresectable or metastatic melanoma following progression on ipilimumab","volume":"23","author":"Hazarika","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.xfre.2025.09.005_bib19","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.4110\/in.2022.22.e2","article-title":"Immune checkpoint inhibitors in 10 years: contribution of basic research and clinical application in cancer immunotherapy","volume":"22","author":"Lee","year":"2022","journal-title":"Immune Netw"},{"key":"10.1016\/j.xfre.2025.09.005_bib20","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.xfre.2025.09.005_bib21","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/bdrb.21176","article-title":"An evaluation of the impact of PD-1 pathway blockade on reproductive safety of therapeutic PD-1 inhibitors","volume":"107","author":"Poulet","year":"2016","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"10.1016\/j.xfre.2025.09.005_bib22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3390\/cancers15010173","article-title":"Immune checkpoint inhibitors and pregnancy: analysis of the VigiBase\u00ae spontaneous reporting system","volume":"15","author":"Noseda","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xfre.2025.09.005_bib23","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/CMR.0000000000000657","article-title":"Conception and viable twin pregnancy in a patient with metastatic melanoma while treated with CTLA-4 and PD-1 checkpoint inhibition","volume":"30","author":"Bucheit","year":"2020","journal-title":"Melanoma Res"},{"key":"10.1016\/j.xfre.2025.09.005_bib24","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.seminoncol.2018.03.003","article-title":"Viable pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapy","volume":"45","author":"Burotto","year":"2018","journal-title":"Semin Oncol"},{"key":"10.1016\/j.xfre.2025.09.005_bib25","first-page":"1","article-title":"Case report of a pregnancy during ipilimumab therapy","volume":"4","author":"Mehta","year":"2018","journal-title":"J Glob Oncol"},{"key":"10.1016\/j.xfre.2025.09.005_bib26","first-page":"762","article-title":"Pregnancy in a patient with metastatic uveal melanoma treated with nivolumab","volume":"19","author":"Haiduk","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.xfre.2025.09.005_bib27","first-page":"4892","article-title":"Effects of hepatic or renal impairment on the pharmacokinetics of immune checkpoint inhibitors","volume":"12","author":"Zhao","year":"2022","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.xfre.2025.09.005_bib28","article-title":"Dosing regimens of immune checkpoint inhibitors: attempts at lower dose, less frequency, shorter course","volume":"12","author":"Jiang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.xfre.2025.09.005_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.836859","article-title":"Immune checkpoint inhibitor-induced hypophysitis and patterns of loss of pituitary function","volume":"12","author":"Jessel","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.xfre.2025.09.005_bib30","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.hoc.2014.02.010","article-title":"State of melanoma: an historic overview of a field in transition","volume":"28","author":"Gorantla","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.xfre.2025.09.005_bib31","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/S1470-2045(18)30500-X","article-title":"Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin\u2019s lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial","volume":"19","author":"Anderson","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.xfre.2025.09.005_bib33","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1634\/theoncologist.2017-0541","article-title":"Long-term survival rates of patients with stage III-IV Hodgkin lymphoma according to age, sex, race, and socioeconomic status, 1984-2013","volume":"23","author":"Li","year":"2018","journal-title":"Oncologist"}],"container-title":["F&S Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666334125001412?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666334125001412?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T09:46:58Z","timestamp":1765446418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666334125001412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2666334125001412"],"URL":"https:\/\/doi.org\/10.1016\/j.xfre.2025.09.005","relation":{},"ISSN":["2666-3341"],"issn-type":[{"value":"2666-3341","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reproductive impact of immune checkpoint inhibitor therapy in women with melanoma","name":"articletitle","label":"Article Title"},{"value":"F&S Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xfre.2025.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of American Society for Reproductive Medicine.","name":"copyright","label":"Copyright"}]}}